44 Biggest Movers From Yesterday
Gainers
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.
Mid-Day Market Update: Nasdaq Down 2%; Xenon Pharmaceuticals Shares Jump
Midway through trading Monday, the Dow traded down 1.02% to 33,976.93 while the NASDAQ fell 2.14% to 14,255.08. The S&P also fell, dropping 1.23% to 4,303.43.
30 Stocks Moving In Monday’s Mid-Day Session
Gainers
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.
OpGen Stock Gains On FDA Approval, Interim Q3 Sales
The FDA has granted 510(k) clearance to OpGen Inc’s (NASDAQ:OPGN) Acuitas AMR Gene Panel. The Company is finalizing preparations for its commercial…
OpGen Receives FDA Clearance For Acuitas AMR Gene Panel
OpGen’s Acuitas® AMR Gene Panel allows testing for a comprehensive panel of 28 genetic AMR markers in isolated bacterial colonies from 26 different pathogens
An aid to clinicians in the management of
18 Stocks Moving in Monday’s Pre-Market Session
Gainers
CohBar, Inc. (NASDAQ: CWBR) rose 22.8% to $1.13 in pre-market trading after dropping over 4% on Friday.
How Good Are OpGen’s Earnings? | Return On Capital Employed
According to data from Benzinga Pro, during Q2, OpGen's (NASDAQ:OPGN) reported sales totaled $811.62 thousand. Despite a 2.94% increase in earnings, the company posted a loss of $6.02 million.